Stella Burns
Overview
Explore the profile of Stella Burns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emmi G, Bettiol A, Gelain E, Bajema I, Berti A, Burns S, et al.
Nat Rev Rheumatol
. 2023 May;
19(6):378-393.
PMID: 37161084
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of...
2.
Roberts D, Jones R, Smith R, Alberici F, Kumaratne D, Burns S, et al.
J Autoimmun
. 2015 Jan;
57:24-9.
PMID: 25586449
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmune diseases, including patients with refractory disease with extensive prior exposure to immunosuppressive treatments. Rituximab, in this...
3.
Roberts D, Jones R, Smith R, Alberici F, Kumaratne D, Burns S, et al.
J Autoimmun
. 2015 Jan;
57:60-5.
PMID: 25556904
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. Hypogammaglobulinemia has occurred after rituximab for lymphoma and rheumatoid arthritis but data are scarce for...
4.
Marco H, Smith R, Jones R, Guerry M, Catapano F, Burns S, et al.
BMC Musculoskelet Disord
. 2014 Jun;
15:178.
PMID: 24884562
Background: Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However,...